Academic and industry partners detail a collaboration to speed discovery of therapies for Alzheimer’s and Parkinson’s, plus translational and talent plans.
Key Takeaways
- Partnership was extended for five years through 2030 to continue joint drug development
- Alliance has supported eight drug discovery projects with a £10 million investment to date
- Anti‑MTBR tau antibody discovered in the collaboration is now in clinical trials for Alzheimer's